Richard B. Moss

Clinical Focus

• Allergy/Asthma/Immunology, Pediatric
• Pulmonary Medicine/Cystic Fibrosis, Pediatric
• Allergy and Immunology

Administrative Appointments

• Director, Allergy-Immunology Fellowship Training Program, Stanford University (2006 - present)
• Co-Director, Children's Health Research Program, Stanford University Medical Center-Lucile Packard Children's Hospital (2006 - present)
• Chief, Allergy-Immunology, Pediatrics, Stanford University (2005 - 2009)
• Director, Cystic Fibrosis Center, Stanford University (1991 - 2009)
• Principal Investigator, CF Therapeutics Development Network Center, Stanford University (1999 - 2009)
View All 9administrative appointments of Richard Moss

Honors and Awards

• Provider of the Year, Cystic Fibrosis Foundation, N. Cal chapter (2008)
• Best Doctors in America, Best Doctors (2001-2009)
• America's Top Pediatricians-Pulmonology, Consumers Research Council of America (2002-2009)
• Professional of the Year, Cystic Fibrosis Research, Inc. (2003)
• Member, American Pediatric Society (2005)

Professional Education

Graduate & Fellowship Program Affiliations

• Immunology
• Pediatrics

Community & International Work

• Project/Grant reviewer 
• Scientific Advisory Board 

Web Site Links

• Stanford Center for Excellence in Pulmonary Biology

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Current Research Interests

I am interested in the pathogenesis of chronic airways diseases of childhood. My work includes basic and clinical research. In the area of basic research, my laboratory has focused on immunoregulation of inflammation in cystic fibrosis, finding deficiencies of activated T cells from CF patients in production of counter-regulatory cytokines (IL-10, IFN-gamma) and redox metabolism. In the arena of clinical research, as a member of the CFF Therapeutics Development Network our research group conducts many trials. I have particular interests in the areas of aerosol therapy with drugs, biologics and gene vectors; mechanisms of pulmonary inflammation and immunomodulatory therapy; and corrrection of CFTR-dependent cell biology defects. We are also investigating new treatments for CF complications such as diabetes and osteoporosis, internet-based disease management, and trials of asthma drugs.

Clinical Trials

• Cystic Fibrosis Registry Recruiting
• GSK study #2110399 in 2010 (Study Drug: SB-656933) Recruiting
• Gilead FTI Study Recruiting
• Inspire Open-Label Extension study Recruiting
• Vertex 770-102 Study Recruiting

Publications

• VX-770, a Novel CFTR Potentiator, in Cystic Fibrosis Patients with the G551D Mutation Accurso FJ, Clancy JP, Rowe SM, Boyle MP, Dunitz J, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein R, Uluer AZ, Aitken ML, Freedman SD, Dong Q, Zha J, Stone AJ, Olson ER, Ordonez CL, Campbell PW, Ashlock MA, Ramsey BW. submitted.
• High frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular disease: an exploratory randomized controlled trial Yuan N, Kane P, Shelton K, Matel J, Becker B, Moss RB. J Child Neurol, accepted..
• Allergic bronchopulmonary aspergillosis Moss RB, eCysticFibrosis Review (http://www.hopkinscme.net/ofp/eCysticFibrosisReview/index.html). 2010
• Ahead of the Curve - Emerging CF Therapies. Pathophysiology and Therapeutic Targets. Moss RB, Johns Hopkins Advanced Studies in Medicine.. 2010 In press.
• Allergic bronchopulmonary aspergillosis Moss RB, In Latge JP, Steinbach WJ, Eds. Aspergillus Fumigatus and Aspergillosis. American Society of Microbiology Press. 2009: 332-350